Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ophirex’s lead drug candidate, LY333013 (varespladib methyl), blocks sPLA2, a nearly ubiquitous and often highly toxic component of venom present in at least 95 percent of snake venoms.
Lead Product(s): Varespladib Methyl
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: LY333013
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AXA IM Prime Impact Master Fund
Deal Size: $37.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 05, 2023